TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25768671
Drug: Stimulated AVP
Normalized name: AVP-21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulated AVP >1.8 pg/mL
Study: 29749403
Drug: Obinutuzumab-bendamustine (G-B)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab-bendamustine (G-B)
Study: 25769620
Drug: Obinutuzumab-fludarabine-cyclophosphamide (G-FC)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab-fludarabine-cyclophosphamide (G-FC)
Study: 25769961
Drug: Residents with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residents with a statement of 'no psychotropic drug prescription' but had a prescription
Study: 25771041
Drug: 0.5% DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% DHEA (prasterone) administered daily intravaginally for 52 weeks
Study: 25771402
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (standard dose: adult 400 mg daily; children 260 mg/m² daily)
Study: 25771402
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (dose escalation regimen: adult 100 mg daily initial dose up to 200 mg daily maximum; children initial dose 65 mg/m² daily up to 130 mg/m² daily)
Study: 25772231
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (Neupro) as add-on to oral PD treatment for ≥1 month
Study: 25772231
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (Neupro)
Study: 25772756
Drug: Motesanib 125
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 125 mg QD with FOLFIRI
Study: 25772756
Drug: Motesanib 125
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 125 mg QD with FOLFOX
Study: 25772756
Drug: Motesanib 125
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 125 mg QD
Study: 25773763
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (1, 2, and 4 mg/24 h)
Study: 25774664
Drug: Insulin-resistant group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-resistant group (HOMA-IR ≥2.6)
Study: 25774664
Drug: Insulin-sensitive group
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitive group (HOMA-IR <2.6)
Study: 25775947
Drug: MCT +
Normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT + treatment-as-usual (TAU)
Study: 25777345
Drug: Sorafenib 200
Normalized name: sorafenib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 200 mg orally b.i.d. with bortezomib 1 mg/m(2) intravenously on days 1, 4, 8, and 11 every 21 days.
Study: 25779580
Drug: Sample collected
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sample collected at optimal time of 4 h after dose, in addition to trough concentration
Study: 25781361
Drug: 1-year outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-year outpatient intervention program based on exercise, behavior, and nutrition therapy
Study: 25782122
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral anticoagulants (NOACs)
Study: 25782401
Drug: Clinician assessment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician assessment of treatment response using Clinical Global Impression scale
Study: 25782401
Drug: Patient assessment
Normalized name: EUA Patient Assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient assessment of treatment response using Subject Global Assessment scale
Study: 25784682
Drug: Carfilzomib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib plus melphalan and prednisone (CMP) at the maximal tolerated dose (MTD) of 36 mg/m².
Study: 25784682
Drug: Carfilzomib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib plus melphalan and prednisone (CMP) at the MTD of 36 mg/m².
Study: 25785226
Drug: Dietary polyunsaturated
Normalized name: OMEGA-3 POLYUNSATURATES
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary polyunsaturated fatty acids (PUFAs) intake in hormone therapy (HT) group
Study: 25785226
Drug: Dietary polyunsaturated
Normalized name: OMEGA-3 POLYUNSATURATES
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary polyunsaturated fatty acids (PUFAs) intake in non-hormone therapy (non-HT) group
Study: 25785995
Drug: pH1N1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH1N1 vaccine (two double doses)
Study: 25786035
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor antagonists (MRAs), n=101
Study: 25786035
Drug: No mineralocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mineralocorticoid receptor antagonists (MRA-Neg), n=101
Study: 25787057
Drug: DMT adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT adherence measured by medication possession ratio (MPR) >0.9
Study: 25787057
Drug: DMT adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT adherence measured by medication possession ratio (MPR) >0.5-<0.9
Study: 25787057
Drug: DMT adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT adherence measured by medication possession ratio (MPR) <0.5
Study: 25787923
Drug: Ramucirumab 6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab 6, 8, or 10 mg/kg Q2W
Study: 25787923
Drug: Ramucirumab 15
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 15 or 20 mg/kg Q3W
Study: 25787923
Drug: Ramucirumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (all doses)
Study: 25789614
Drug: Methacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine inhalation test (MIT)
Study: 25789989
Drug: Omalizumab (anti-IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (anti-IgE treatment) administered for 12 weeks
Study: 25793152
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg weekly for 12 weeks
Study: 25793933
Drug: Diethylcarbamazine and
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine and albendazole (DEC/Alb) - single dose
Study: 25794243
Drug: Mobile Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobile Insulin Titration Intervention (MITI) - texting/phone call intervention
Study: 25794535
Drug: Volasertib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib plus cisplatin (100 mg/m(2))
Study: 25795132
Drug: Gene-mediated cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene-mediated cytotoxic immunotherapy (GMCI) with AdV-tk + prodrug in Arm A
Study: 25795132
Drug: Gene-mediated cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene-mediated cytotoxic immunotherapy (GMCI) with AdV-tk + prodrug in Arm B
Study: 25795402
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m²) followed by Trabectedin (1.1 mg/m²) and Pegfilgrastim (6 mg) every 3 weeks for up to six cycles
Study: 25795637
Drug: Nintedanib 100-450
Normalized name: nintedanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 100-450 mg once daily (n = 40)
Study: 25795637
Drug: Nintedanib 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 250 mg b.i.d. (n = 11)
Study: 25795637
Drug: Nintedanib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (various doses)
Study: 26199039
Drug: Maximum tolerated
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum tolerated dose (MTD)
Study: 25795722
Drug: Resimmune (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resimmune (2.5 - 11.25 μg/kg intravenous infusion over 15 minutes)
Study: 25798215
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplements (1.5 g)
Study: 25800136
Drug: Baseline glomerular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline glomerular filtration rate < 30 mL/min
Study: 25800893
Drug: Decreasing minimal
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreasing minimal residual disease levels between end of induction and week 7 of maintenance therapy
Study: 25801562
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy including telaprevir
Study: 25801567
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate 300 mg once daily
Study: 25801567
Drug: Low body
Normalized name: Lotion, Multi Ingredient Topical application Lotion [ALPHA GLOW BODY CARE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low body weight, low eGFR, concomitant use of ritonavir-boosted protease inhibitors
Study: 25802729
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (diet/exercise alone or diet/exercise plus oral antihyperglycemic drug)
Study: 25802932
Drug: Nimotuzumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab (200 mg/m² weekly for 4 weeks, then concurrent with gemcitabine (800 mg/m²) or cisplatin (50 mg/m²) for 18 weeks, then maintenance every 2 weeks)
Study: 25802932
Drug: Concurrent phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent phase with chemotherapy (gemcitabine or cisplatin)
Study: 25802932
Drug: Nimotuzumab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab (single agent during induction and maintenance phases)
Study: 25803093
Drug: Bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 500 mg + Rifampin 600 mg
Study: 25803268
Drug: Histrelin subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histrelin subcutaneous implant
Study: 25804941
Drug: G-CSF with/without
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF with/without chemotherapy
Study: 25804941
Drug: G-CSF without
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF without plerixafor
Study: 25806291
Drug: Erlotinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib treatment with low/intermediate ROR1 levels
Study: 25806291
Drug: Erlotinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib treatment with high ROR1 levels
Study: 25806291
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment with low/intermediate ROR1 levels
Study: 25806291
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment with high ROR1 levels
Study: 25806291
Drug: Erlotinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib treatment with T790M mutation and low/intermediate ROR1 levels
Study: 25806291
Drug: Erlotinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib treatment with T790M mutation and high ROR1 levels
Study: 25806291
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment with T790M mutation and low/intermediate ROR1 levels
Study: 25806291
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment with T790M mutation and high ROR1 levels
Study: 25807932
Drug: Lisinopril (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (0.1 mg/kg/day)
Study: 25809054
Drug: Comprehensive geriatric
Normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive geriatric assessments, clinical and diagnostic information, biological and molecular markers.
Study: 25809731
Drug: NVP-AUY922 monotherapy
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP-AUY922 monotherapy
Study: 25809824
Drug: Cabazitaxel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (25 mg/m² every 3 weeks plus daily prednisolone)
Study: 25810005
Drug: G-CSF primary
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF primary prophylaxis orders
Study: 25810005
Drug: G-CSF orders
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF orders relative to physician's FN risk intervention threshold
Study: 25812009
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg glipizide × 1
Study: 25812009
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg metformin × 2 days
Study: 25812924
Drug: Subretinal visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal visual implant (Alpha IMS)
Study: 25815033
Drug: Passive control
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive control (no treatment)
Study: 25818754
Drug: 4 contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 contrast agents used in Coronary CT angiography
Study: 25819643
Drug: Tremelimumab 10
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab 10 mg/kg once every 4 weeks for six doses, then every 12 weeks until disease progression, unacceptable toxic effects, or refusal to continue treatment.
Study: 25821795
Drug: 173*CC genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: 173*CC genotype
Study: 25822727
Drug: Unicirc instrument
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unicirc instrument with topical lidocaine/prilocaine anesthetic
Study: 25822820
Drug: Agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agalsidase alfa (agalα; 0.2 mg/kg every other week)
Study: 25823600
Drug: No Oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Oral Immunotherapy (No OIT)
Study: 25823737
Drug: Tumor-infiltrating T
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor-infiltrating T cells selected for HPV E6 and E7 reactivity (HPV-TILs) infused after lymphocyte-depleting chemotherapy and followed by aldesleukin administration.
Study: 25823737
Drug: HPV-TILs infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HPV-TILs infusion product
Study: 25823737
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of HPV-reactive T cells in peripheral blood 1 month after treatment
Study: 25823919
Drug: Buprenorphine-naloxone buccal
Normalized name: buprenorphine / naloxone Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone buccal film (BBN)
Study: 25824215
Drug: Rifapentine 10
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 10 mg/kg twice daily for 14 days
Study: 25824215
Drug: Rifapentine 20
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 20 mg/kg once daily for 14 days
Study: 25824215
Drug: Rifapentine 15
Normalized name: rifapentine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine 15 mg/kg once daily with a high-fat breakfast
Study: 25824215
Drug: Rifapentine divided
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine divided dosing (e.g., 1,500 mg/day)
Study: 25824314
Drug: Rheolytic thrombectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheolytic thrombectomy (RT) without lytic agent
Study: 25824314
Drug: RT in
Normalized name: Aspart Insulin
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RT in combination with CDT
Study: 25824314
Drug: Rheolytic PCDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheolytic PCDT treatment
Study: 25825476
Drug: Afatinib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (20 mg/d) and trastuzumab (6 mg/kg/3 weeks) for 6 weeks, followed by paclitaxel (80 mg/m2/1 week), trastuzumab, and afatinib for 12 weeks, followed by epirubicin (90 mg/m2/3 weeks), cyclophosphamide (600 mg/m2/3 weeks), and trastuzumab for 12 weeks
Study: 25825625
Drug: Community health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community health worker (CHW) administered stroke symptom questionnaire (QVSFS)
Study: 25827820
Drug: MK-2206 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 (60 mg every other day)
Study: 25827941
Drug: Dalteparin (subcutaneous)
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (subcutaneous) for 12 months
Study: 25829395
Drug: Sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4 mg kg(-1)
Study: 25829804
Drug: Abcertin® administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abcertin® administered at the same dose as imiglucerase (30 to 55 U/kg every other week) for 24 weeks
Study: 25832001
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN-α) treatment
Study: 25833390
Drug: Bortezomib in
Normalized name: bortezomib Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib in combination with ifosfamide and vinorelbine (IVB)
Study: 25834212
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) 40 mg every other week for up to 12 weeks or 20 weeks
Study: 25837499
Drug: Lenalidomide 15
Normalized name: lenalidomide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 15 mg daily
Study: 25837499
Drug: Lenalidomide 20
Normalized name: lenalidomide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 20 mg daily
Study: 25837499
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 intravenously (days 1, 8, and 15)
Study: 25837499
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) as prophylactic anticoagulant
Study: 25837499
Drug: Overall treatment-related
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment-related adverse events (AEs)
Study: 25837801
Drug: Early levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early levosimendan administration (perioperatively up to the first hour after ICU admission)
Study: 25837801
Drug: Late levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late levosimendan administration (later than the first hour after ICU admission)
Study: 25844160
Drug: 12-week PATCH
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week PATCH intervention + usual care
Study: 25846031
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal system (≤ 14 mg/24 h; dose adjustments ≤ 16 mg/24 h permitted)
Study: 25846669
Drug: Intratumoral TG1042
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral TG1042 injection (adenovirus expressing IFN-γ) combined with tumor-infiltrating lymphocytes (TILs)
Study: 25847227
Drug: Glass-based yttrium
Normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass-based yttrium 90 therapy
Study: 25847929
Drug: Gemcitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,000 mg/m(2) IV on days 1 and 8), Carboplatin (AUC 2 IV on days 1 and 8), Iniparib (5.6 mg/kg IV on days 1, 4, 8, and 11) administered every 21 days for four cycles (amended to six cycles).
Study: 25847936
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m(2) every 3 weeks)
Study: 25848948
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous vitamin C (IVC) combined with chemotherapy
Study: 25848948
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous vitamin C (IVC)
Study: 25849571
Drug: Sequential Organ
Normalized name: argan oil
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores
Study: 25849721
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg three times daily for ≥2 weeks
Study: 25852820
Drug: Adjuvant Adriamycin-based
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant Adriamycin-based chemotherapy with increased BFI scores (32 patients)
Study: 25852962
Drug: End-tidal CO2
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-tidal CO2 (EtCO2) monitoring using a dedicated naso-buccal sensor during non-invasive ventilation (NIV)
Study: 25853747
Drug: Ibrutinib at
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib at a daily dose of 420 mg
Study: 25855376
Drug: Prophylaxis (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis (recombinant FVIII-FS 20-30 IU/kg thrice weekly)
Study: 25855621
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day, oral) until disease progression, intolerable toxicity or death
Study: 25855621
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day, oral) in non-smokers with adenocarcinoma